Catalent Pharma Solutions has reached an exclusive development and licensing agreement with Cingulate Therapeutics (CTx) to support formulation development of a series of new drug products to treat Attention Deficit/Hyperactivity Disorder (ADHD) using Catalent’s OSDrC OptiDose drug delivery platform.   The products, CTX-1301 and CTX-1302, are currently in preclinical development and are designed to address several unmet patient needs with ADHD. The company’s lead product, CTX-1301, is expected t...